Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

W Theelen; HMU Peulen; F Lalezari; V van der Noort; JF de Vries; Joachim Aerts; Daphne Dumoulin; I Bahce; ALN Niemeijer; AJ de Langen; K Monkhorst; P Baas

doi:10.1001/jamaoncol.2019.1478

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

W Theelen, HMU Peulen, F Lalezari, V van der Noort, JF de Vries, Joachim Aerts, Daphne Dumoulin, I Bahce, ALN Niemeijer, AJ de Langen, K Monkhorst, P Baas

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

424 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1276-1282
Number of pages	7
Journal	JAMA Oncology
Volume	5
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2019.1478
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamaoncol.2019.1478

http://hdl.handle.net/1765/118115

Cite this

Theelen, W., Peulen, HMU., Lalezari, F., van der Noort, V., de Vries, JF., Aerts, J., Dumoulin, D., Bahce, I., Niemeijer, ALN., de Langen, AJ., Monkhorst, K., & Baas, P. (2019). Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5(9), 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478

@article{4c39f339eb0a4aefa4db2a349ce68ccb,

title = "Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial",

author = "W Theelen and HMU Peulen and F Lalezari and {van der Noort}, V and {de Vries}, JF and Joachim Aerts and Daphne Dumoulin and I Bahce and ALN Niemeijer and {de Langen}, AJ and K Monkhorst and P Baas",

year = "2019",

doi = "10.1001/jamaoncol.2019.1478",

language = "Undefined/Unknown",

volume = "5",

pages = "1276--1282",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "9",

}

Theelen, W, Peulen, HMU, Lalezari, F, van der Noort, V, de Vries, JF, Aerts, J , Dumoulin, D, Bahce, I, Niemeijer, ALN, de Langen, AJ, Monkhorst, K & Baas, P 2019, 'Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial', JAMA Oncology, vol. 5, no. 9, pp. 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. / Theelen, W; Peulen, HMU; Lalezari, F et al.

In: JAMA Oncology, Vol. 5, No. 9, 2019, p. 1276-1282.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

AU - Theelen, W

AU - Peulen, HMU

AU - Lalezari, F

AU - van der Noort, V

AU - de Vries, JF

AU - Aerts, Joachim

AU - Dumoulin, Daphne

AU - Bahce, I

AU - Niemeijer, ALN

AU - de Langen, AJ

AU - Monkhorst, K

AU - Baas, P

PY - 2019

Y1 - 2019

U2 - 10.1001/jamaoncol.2019.1478

DO - 10.1001/jamaoncol.2019.1478

M3 - Article

VL - 5

SP - 1276

EP - 1282

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 9

ER -